Ethnicity and disease severity in ankylosing spondylitis

Ethnicity and disease severity in ankylosing spondylitis

A cross-sectional analysis of three ethnic groups

By Spondylitis Association of America

A person’s genetic makeup, including HLA-B27, is thought to make up roughly 90% of the disease risk in ankylosing spondylitis (AS.)1 It’s not surprising then that ethnicity plays a large role in the frequency of AS throughout the world. New research now suggests that ethnicity may also play a role in disease activity and severity.

Clinical Trial Opportunity for Adults with Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Clinical Trial Opportunity for Adults with Non-radiographic Axial Spondyloarthritis (nr-axSpA)

By Spondylitis Association of America

A phase 3 clinical trial is now recruiting non-radiographic axial Spondyloarthritis (nr-axSpA) patients over the age of 18 to participate in a study of an investigational biologic medication, secukinumab, given by injection.

Guide to Healthy Habits for a Work-Life Balance

Guest Blog Post

By The George Washington University

In an increasingly connected and busy world, workers in many fields complain about working themselves “to death” in an attempt to “have it all.” While the phrase is often meant as hyperbole, studies continue to find that heavy workloads, family stressors, decreased free time and unhealthy personal habits really are dangerous for our health. 

SAA’s Spondylitis Educational Seminar from San Diego, CA

SAA’s Spondylitis Educational Seminar from San Diego, CA

Rheumatologist John Reveille & Physical Therapist Angelo Papachristos

By Spondylitis Association of America

On November 4, 2017 the Spondylitis Association of America hosted a free Spondylitis Educational Seminar in San Diego, CA. Our speakers for the day were Rheumatologist John Reveille, MD and Physical Therapist Angelo Papachristos, MBA, BSc (PT).

Taltz® (ixekizumab) Now FDA Approved for Psoriatic Arthritis Patients

Taltz® (ixekizumab) Now FDA Approved for Psoriatic Arthritis Patients

By Spondylitis Association of America

As of December 1, 2017, the FDA has officially approved Taltz injection 80 mg/mL for treatment of patients with active psoriatic arthritis.

RSS
First9101112131415161718Last

Stay Informed

Text/HTML

Careers

Visit our careers page for available positions

Contact Us

Spondylitis Association of America

16360 Roscoe Blvd.  Ste. 100
Van Nuys, CA 91406

Email

info@spondylitis.org

Information Requests

(800) 777-8189 U.S. only
or (818) 892-1616
*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.

Give With Confidence